Download sample

Dementia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dementia Overview 9
Therapeutics Development 10
Pipeline Products for Dementia - Overview 10
Pipeline Products for Dementia - Comparative Analysis 11
Dementia - Therapeutics under Development by Companies 12
Dementia - Therapeutics under Investigation by Universities/Institutes 15
Dementia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Dementia - Products under Development by Companies 20
Dementia - Products under Investigation by Universities/Institutes 24
Dementia - Companies Involved in Therapeutics Development 25
Adamas Pharmaceuticals, Inc. 25
AgeneBio Inc. 26
Alector LLC 27
AlzProtect SAS 28
Amarantus Bioscience Holdings, Inc. 29
Axon Neuroscience SE 30
Axovant Sciences Ltd. 31
BioArctic Neuroscience AB 32
Biogen, Inc. 33
Biotie Therapies Corp. 34
Boehringer Ingelheim GmbH 35
Chase Pharmaceuticals Corporation 36
Daewoong Pharmaceutical Co., Ltd. 37
Eisai Co., Ltd. 38
FORUM Pharmaceuticals Inc. 39
H. Lundbeck A/S 40
Heptares Therapeutics Limited 41
Hyundai Pharmaceutical Co., Ltd. 42
Ildong Pharmaceutical Co., Ltd. 43
Immungenetics AG 44
ImStar Therapeutics Inc. 45
Integrative Research Laboratories Sweden AB 46
Intellect Neurosciences, Inc. 47
Intra-Cellular Therapies, Inc. 48
MediPost Co., Ltd. 49
Neuraltus Pharmaceuticals, Inc. 50
Neurimmune Holding AG 51
Neurodyn Inc. 52
Oryzon Genomics S.A. 53
Ovid Therapeutics Inc. 54
P2D Bioscience 55
Pacific Northwest Biotechnology, LLC 56
Pivot Pharmaceuticals Inc 57
Sinil Pharmaceutical Co., Ltd 58
Stelic Institute & Co., Inc. 59
Sumitomo Dainippon Pharma Co., Ltd. 60
Sylentis S.A.U. 61
TauRx Therapeutics Ltd. 62
WhanIn Pharmaceutical Co., Ltd. 63
Dementia - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Target 66
Assessment by Mechanism of Action 69
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 76
AADvac-1 - Drug Profile 77
Antisense Oligonucleotides to Inhibit microRNA for Neurology - Drug Profile 78
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 79
AVCRI-104P3 - Drug Profile 80
AZP-2006 - Drug Profile 81
BAN-0805 - Drug Profile 83
BI-409306 - Drug Profile 84
CB-2233 - Drug Profile 86
CB-8411 - Drug Profile 87
choline alfoscerate SR - Drug Profile 88
CPC-201 - Drug Profile 89
CPC-252 - Drug Profile 90
D-217 - Drug Profile 91
dehydroevodiamine hydrochloride - Drug Profile 92
Drugs for Dementia - Drug Profile 93
Drugs to Agonize c-MET for Dementia - Drug Profile 94
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 95
DWJ-1365 - Drug Profile 96
E-2609 - Drug Profile 97
eltoprazine - Drug Profile 98
encenicline hydrochloride - Drug Profile 101
FRM-0334 - Drug Profile 104
GIBH-130 - Drug Profile 106
Gln-1062 - Drug Profile 107
GTC-6000 - Drug Profile 109
gugulipid - Drug Profile 110
HOB-075 - Drug Profile 111
HTL-18318 - Drug Profile 112
IRL-752 - Drug Profile 113
ITI-007 - Drug Profile 114
KR-12 - Drug Profile 116
levetiracetam - Drug Profile 117
LH-026 - Drug Profile 118
LUAF-20513 - Drug Profile 119
MM-201 - Drug Profile 120
Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile 121
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 122
NAT - Drug Profile 123
nelotanserin - Drug Profile 124
Neurostem - Drug Profile 125
NI-205 - Drug Profile 127
NI-308 - Drug Profile 128
NNC-269100 - Drug Profile 129
NP-001 - Drug Profile 130
OG-635 - Drug Profile 131
ORY-2001 - Drug Profile 132
OV-201 - Drug Profile 134
P-003 - Drug Profile 135
PD-2015 - Drug Profile 136
PD-2016 - Drug Profile 137
PD-2024 - Drug Profile 138
PD-2244 - Drug Profile 139
PD-61W3 - Drug Profile 140
Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 141
PST-900 - Drug Profile 142
RVT-101 - Drug Profile 143
salicylamine - Drug Profile 144
SIN-1502 - Drug Profile 145
Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 146
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 147
Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 148
Small Molecules for Frontotemporal Dementia - Drug Profile 149
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 150
Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 151
Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease
Dementia - Drug Profile 152
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile 153
SND-14 - Drug Profile 154
SYN-120 - Drug Profile 155
Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 156
TAK-070 - Drug Profile 157
TauC-3 - Drug Profile 158
TPI-287 - Drug Profile 159
TRx-0237 - Drug Profile 162
TTT-3002 - Drug Profile 164
WIB-1001C - Drug Profile 165
zonisamide - Drug Profile 166
Dementia - Recent Pipeline Updates 167
Dementia - Dormant Projects 194
Dementia - Discontinued Products 199
Dementia - Product Development Milestones 200
Featured News & Press Releases 200
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 212
Disclaimer 213